Patient/subject characteristics for total populations with severe asthma from included articles (12 articles and 12 populations)
| First author (year), study or cohort name [reference] | Subjects | Age, years | Male, % | FEV1, % predicted | ICS use, %# | Comorbidities, %¶ |
| Heffler (2019) SANI [102] | 437 | 54.1±13.7 | 42.8 | 71.4±20.2 | 100 | Atopy: 70.7; perennial AR: 62.2; NP±CRS: 42.6; AR: 44.6; FA: 8.7 |
| Haughney (2018) [71] | 884 | 54.7±15.9 | 31.3 | 24.9§ (+LABA: 96.4§) | COPD: 32.5; T1/2D: 13.9; CVD: 12.2; OSP: 4.3; depression: 5.7; NP±CRS: 1.0 | |
| Husereau (2018) [103] | 212ƒ | 43±16 | 42 | +LABA: 100## | T1/2D: 7; AR: 9; atopy: 7; anxiety: 9; depression: 3 | |
| Lima-Matos (2018) [49] | 544 | 52 (43–61) | 19 | 70 (58–81)postBD | 38 | |
| Maio (2018) RItA [72] | 493 | 53.8±13.4 (n=483) | 39.40 | 75.1±20.5 (n=477) | 97.1 (+LABA: 93.6) (n=488) | COPD: 11.8; aspirin sensitivity: 22; NP±CRS: 30.2; AR: 62.4 |
| Teague (2018) SARP III [45] | 313 | 49.7±12.8 | 32.9 | 77.9±19.7max. postBD | ||
| Chipps (2018) TENOR II [104] | 341 | 57.8±16.3 | 34.6 | 78.9±20.6¶¶,postBD | 84.0 (+LABA: 71.0) | COPD: 12.6; T1/2D: 0.6/15.5; CHF: 2.3; CAD: 5.6; OHD: 10.6; aspirin sensitivity: 19.4; NP±CRS: 21.4; AR: 84.1; FA: 30.5; OSP: 15.8; urticaria: 15.5; malignancy: 9.7 |
| Pretolani (2017) COBRA [50]+ | 613 | 51.1±14.72 | 34.75 | 74.13±33.00preBD | 98.84++ | Atopy: 86.38; AR: 65.84; NP±CRS: 30.92; CVD: 20.59; FA: 14.80 |
| Zeiger (2017) [105] | 261 | 52.1±16.1 | 33.3 | 25.7 (+LABA: 87.0) | NP±CRS: 5.7; AR: 59.0; atopy: 2.7; anxiety: 17.2; depression: 19.9 | |
| Chaudhuri (2016) [73] | 1042 | 49.3±14.1 | 34.7 | 71.0 (51.0–87.0) (n=947)preBD | 100 (n=993) | Atopy: 75.1; perennial AR: 35.7; NP±CRS: 13.8; CVD: 6.7; T1/2D: 4.3 |
| Newby (2014) BTS Severe Refractory Asthma [74] | 349 | 45.80±4.2 (n=349)§§ | 36.4 | 66±24 (n=330)preBD | Atopy: 58.4; perennial AR: 29.1; AR: 37.9; eczema: 27.9; NP±CRS: 13.5 | |
| Schleich (2014) BSAR [106] | 350 | 55±0.8 | 43 | 68±1.2 | Atopy: 70; CRS: 49; overweight: 47; GORD: 36; NP±CRS: 19; depression: 19; bronchiectasis: 16 |
Data are presented as n, mean±sd or median (interquartile range (25th–75th percentile)), unless otherwise stated. Empty cells indicate that data were not reported in the study/article. FEV1: forced expiratory volume in 1 s; ICS: inhaled corticosteroid; SANI: Severe Asthma Network in Italy; RItA: the Italian severe/uncontrolled asthma registry; SARP: Severe Asthma Research Program; TENOR: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens; COBRA: Cohort of Bronchial Obstruction and Asthma; BTS: British Thoracic Society; BSAR: Belgian Severe Asthma Registry; LABA: long-acting β2-agonist; T1/2D: type 1/2 diabetes; CVD: cardiovascular disease; OSP: osteoporosis; NP: nasal polyps; CRS: chronic rhinosinusitis; AR: allergic rhinitis; FA: food allergy; BD: bronchodilator; max: maximum; CHF: congestive heart failure; CAD: coronary artery disease; OHD: other heart disease; GORD: gastro-oesophageal reflux disease. #: data represent baseline values, unless otherwise indicated; ¶: CVD excludes high blood pressure; atopy includes eczema; perennial AR includes perennial allergen sensitisation; +: publications for which data for the total population were calculated from the available published subgroup data (no data for the total population were originally reported); §: at least one prescription 2 years prior to index date; ƒ: eosinophil data available for n=212; ##: at index date; ¶¶: Global Lung Function Initiative estimates of percentage predicted pre-BD and post-BD FEV1; ++: time of assessment not reported; §§: derived values.